Abstract
We studied 41 patients suffering from pharmacoresistant focal epilepsy, medicated with PHT (22 patients) or CBZ (19 patients) to which LTG was gradually added. 25 patients dropped out during LTG add-on phase: 1 for withdrawal of consent, 5 for treatment failure, 4 for adverse events and 15 because the reduction of seizure number during PHT or CBZ withdrawal so they continued with LTG + PHT or LTG + CBZ. One of the patients died suddenly while on LTG + CBZ treatment. 10 patients completed the study reaching LTG monotherapy, of these 3 reached a complete seizure control, 4 had a seizure reduction higher than 50%, while 3 showed a seizure reduction between 6 and 36%. The LTG plasma concentration of the patients which completed the study with LTG monotherapy varied between 3,3 and 11,2 μg/ml (median 6,1) with a wide intraindividual variability notwithstanding the same LTG daily dose. The drawbacks of the study protocol are discussed as well as the problem of sudden unexplained death occurring in patients treated with LTG. These results should be confirmed by the final analysis of the international study owing to the limited sample of evaluated patients.
| Original language | Italian |
|---|---|
| Pages (from-to) | 135-137 |
| Number of pages | 3 |
| Journal | Bollettino - Lega Italiana contro l'Epilessia |
| Issue number | 86-87 |
| Publication status | Published - 1994 |
Fingerprint
ASJC Scopus subject areas
- Clinical Neurology
Cite this
STUDIO MULTICENTRICO SULL'EFFICACIA DELLA LAMOTRIGINA : OSSERVAZIONI CLINICHE E METODOLOGICHE IN UN GRUPPO DI PAZIENTI. / Zagnoni, P. G.; Giubergia, S.; Zaccara, G.; Muscas, G. C.; Tartara, A.; Manni, R.; Cornaggia, C. M.; Gianetti, S.; Binelli, S.; Avanzini, G.
In: Bollettino - Lega Italiana contro l'Epilessia, No. 86-87, 1994, p. 135-137.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - STUDIO MULTICENTRICO SULL'EFFICACIA DELLA LAMOTRIGINA
T2 - OSSERVAZIONI CLINICHE E METODOLOGICHE IN UN GRUPPO DI PAZIENTI
AU - Zagnoni, P. G.
AU - Giubergia, S.
AU - Zaccara, G.
AU - Muscas, G. C.
AU - Tartara, A.
AU - Manni, R.
AU - Cornaggia, C. M.
AU - Gianetti, S.
AU - Binelli, S.
AU - Avanzini, G.
PY - 1994
Y1 - 1994
N2 - We studied 41 patients suffering from pharmacoresistant focal epilepsy, medicated with PHT (22 patients) or CBZ (19 patients) to which LTG was gradually added. 25 patients dropped out during LTG add-on phase: 1 for withdrawal of consent, 5 for treatment failure, 4 for adverse events and 15 because the reduction of seizure number during PHT or CBZ withdrawal so they continued with LTG + PHT or LTG + CBZ. One of the patients died suddenly while on LTG + CBZ treatment. 10 patients completed the study reaching LTG monotherapy, of these 3 reached a complete seizure control, 4 had a seizure reduction higher than 50%, while 3 showed a seizure reduction between 6 and 36%. The LTG plasma concentration of the patients which completed the study with LTG monotherapy varied between 3,3 and 11,2 μg/ml (median 6,1) with a wide intraindividual variability notwithstanding the same LTG daily dose. The drawbacks of the study protocol are discussed as well as the problem of sudden unexplained death occurring in patients treated with LTG. These results should be confirmed by the final analysis of the international study owing to the limited sample of evaluated patients.
AB - We studied 41 patients suffering from pharmacoresistant focal epilepsy, medicated with PHT (22 patients) or CBZ (19 patients) to which LTG was gradually added. 25 patients dropped out during LTG add-on phase: 1 for withdrawal of consent, 5 for treatment failure, 4 for adverse events and 15 because the reduction of seizure number during PHT or CBZ withdrawal so they continued with LTG + PHT or LTG + CBZ. One of the patients died suddenly while on LTG + CBZ treatment. 10 patients completed the study reaching LTG monotherapy, of these 3 reached a complete seizure control, 4 had a seizure reduction higher than 50%, while 3 showed a seizure reduction between 6 and 36%. The LTG plasma concentration of the patients which completed the study with LTG monotherapy varied between 3,3 and 11,2 μg/ml (median 6,1) with a wide intraindividual variability notwithstanding the same LTG daily dose. The drawbacks of the study protocol are discussed as well as the problem of sudden unexplained death occurring in patients treated with LTG. These results should be confirmed by the final analysis of the international study owing to the limited sample of evaluated patients.
UR - http://www.scopus.com/inward/record.url?scp=0028674550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028674550&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0028674550
SP - 135
EP - 137
JO - Bollettino - Lega Italiana contro l'Epilessia
JF - Bollettino - Lega Italiana contro l'Epilessia
SN - 0394-560X
IS - 86-87
ER -